Joincare Pharmaceutical Group Industry Co., Ltd (SHA: 600380), a Chinese pharmaceutical company, has announced a strategic cooperation and licensing agreement with Jiangsu QYuns Therapeutics Co., Ltd concerning QX008N, a monoclonal antibody (mAb) that targets thymic stromal lymphopoietin (TSLP). According to the agreement, Joincare will secure exclusive rights to research and develop, manufacture, and commercialize QX008N in mainland China, Hong Kong, and Macau, while QYuns will retain these rights for all other territories. Financial specifics of the deal were not disclosed.
The Category 1 biologic, which has received approval for clinical trials in asthma and moderate to severe chronic obstructive pulmonary disease (COPD) in China, as well as severe asthma in the US, is currently in a Phase Ib clinical study for asthma in China.- Flcube.com
